Soleno Therapeutics (NASDAQ: SLNO) is one of 80 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its peers? We will compare Soleno Therapeutics to related companies based on the strength of its analyst recommendations, institutional ownership, risk, earnings, dividends, valuation and profitability.

Valuation & Earnings

This table compares Soleno Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Soleno Therapeutics $1.45 million -$12.06 million -0.83
Soleno Therapeutics Competitors $975.11 million $120.37 million 223.43

Soleno Therapeutics’ peers have higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Soleno Therapeutics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soleno Therapeutics 0 0 1 0 3.00
Soleno Therapeutics Competitors 218 1242 2654 95 2.62

Soleno Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 370.59%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 8.43%. Given Soleno Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Soleno Therapeutics is more favorable than its peers.


This table compares Soleno Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soleno Therapeutics -1,389.76% -54.11% -46.95%
Soleno Therapeutics Competitors -427.68% -43.56% -12.63%

Risk and Volatility

Soleno Therapeutics has a beta of 5.99, meaning that its stock price is 499% more volatile than the S&P 500. Comparatively, Soleno Therapeutics’ peers have a beta of 0.94, meaning that their average stock price is 6% less volatile than the S&P 500.

Insider & Institutional Ownership

65.7% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 69.8% of Soleno Therapeutics shares are held by insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Soleno Therapeutics peers beat Soleno Therapeutics on 7 of the 12 factors compared.

About Soleno Therapeutics

Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with's FREE daily email newsletter.